Aptar Pharma has announced that a new budesonide DPI launched in China by Shanghai Sine Promod Pharmaceutical is the first marketed product to incorporate Aptar’s new Twister device. The new 200µg dose budesonide inhaler is available in 30 capsule and 60 capsule versions for the treatment of asthma.
In April 2012, Aptar Pharma announced the availability of the Twister inhaler, which was developed at the company’s Center of Excellence in Le Vaudreuil, France. Made of transparent plastic, the inhaler is designed with a minimal number of components, and operation of the device includes only three steps — insert, twist, inhale. Audio cues are provided to the patient during inhalation.
Aptar Pharma VP of Northeast Asia Yan Jiang commented, “Shanghai Sine Promod Pharmaceutical Co., Ltd is one of Aptar Pharma’s key customers in China. We are particularly proud to have supported their Budesonide DPI program through the development and commercialization of Twister, manufactured locally in our Suzhou facility. This is a very important milestone for Aptar Pharma China.”
Read the Aptar Pharma press release.
